Critical Contrast: Aurinia Pharmaceuticals (NASDAQ:AUPH) & Puma Biotechnology (NASDAQ:PBYI)

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Puma Biotechnology (NASDAQ:PBYI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aurinia Pharmaceuticals and Puma Biotechnology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	2	1	2.67
Puma Biotechnology	0	2	0	0	2.00

Aurinia Pharmaceuticals currently has a consensus target price of $17.67, indicating a potential upside of 8.93%. Puma Biotechnology has a consensus target price of $6.00, indicating a potential downside of 39.58%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Puma Biotechnology.

Institutional & Insider Ownership

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Aurinia Pharmaceuticals and Puma Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Puma Biotechnology	11.50%	20.76%	13.22%

Volatility & Risk

Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and Puma Biotechnology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	7.62	$287.20 million	$2.29	7.08
Puma Biotechnology	$228.40 million	2.24	$31.11 million	$0.52	19.10

Aurinia Pharmaceuticals has higher revenue and earnings than Puma Biotechnology. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Summary

Aurinia Pharmaceuticals beats Puma Biotechnology on 12 of the 15 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About Puma Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.